Nail outcome improvements with certolizumab pegol in moderate to severe plaque psoriasis: results from phase 3 trials

被引：0
|
作者：
Gottlieb, A. B. [1 ]
Thaci, D. [2 ]
Leonardi, C. [3 ,4 ]
Poulin, Y. [5 ]
Kavanagh, S. [6 ]
Boehnlein, M. [7 ]
Reich, K. [8 ,9 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Lubeck, Lubeck, Germany
[3] Cent Dermatol, St Louis, MO USA
[4] St Louis Univ, Sch Med, St Louis, MO USA
[5] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada
[6] UCB Pharma, Raleigh, NC USA
[7] UCB Pharma, Monheim, Germany
[8] SCIderm Res Inst, Hamburg, Germany
[9] Dermatologikum Berlin, Berlin, Germany
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷
关键词：
Certolizumab Pegol; Nail disease; Psoriasis;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P116
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [41] Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis Analysis of Results From 3 Randomized Phase 3 Clinical Trials
    Armstrong, April W.
    Lynde, Charles W.
    McBride, Sandy R.
    Stahle, Mona
    Edson-Heredia, Emily
    Zhu, Baojin
    Amato, David
    Nikai, Enkeleida
    Yang, Fan Emily
    Gordon, Kenneth B.
    [J]. JAMA DERMATOLOGY, 2016, 152 (06) : 661 - 669
  • [42] Durability of response in plaque psoriasis patients treated with certolizumab pegol: Two year data from the CIMPASI-1 and CIMPASI-2 phase 3 trials
    Gordon, Kenneth
    Reich, Kristian
    Blauvelt, Andrew
    Thaci, Diamant
    Leonardi, Craig
    Poulin, Yves
    Boehnlein, Marion
    Kavanagh, Sarah
    Arendt, Catherine
    Gottlieb, Alice B.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB195 - AB195
  • [43] Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
    Langley, Richard G.
    Elewski, Boni E.
    Lebwohl, Mark
    Reich, Kristian
    Griffiths, Christopher E. M.
    Papp, Kim
    Puig, Lluis
    Nakagawa, Hidemi
    Spelman, Lynda
    Sigurgeirsson, Bardur
    Rivas, Enrique
    Tsai, Tsen-Fang
    Wasel, Norman
    Tyring, Stephen
    Salko, Thomas
    Hampele, Isabelle
    Notter, Marianne
    Karpov, Alexander
    Helou, Silvia
    Papavassilis, Charis
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (04): : 326 - 338
  • [44] Efficacy and safety of efalizumab in a large cohort of patients with moderate to severe plaque psoriasis: Pooled results from randomized phase III trials
    Gordon, K
    Pariser, D
    Langley, R
    Caro, I
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P1 - P1
  • [45] Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study
    Korge, Bernhard
    Vanhooteghem, Olivier
    Lynde, Charles W.
    Machovcova, Alena
    Perrussel, Marc
    Lazaridou, Elisavet
    Marasca, Claudio
    Sarro, David Vidal
    Pousa, Ines Duenas
    Fierens, Frederik
    Williams, Paulette
    Shimizu, Saori
    Heidbrede, Tanja
    Warren, Richard B.
    [J]. DERMATOLOGY AND THERAPY, 2024, 14 (08) : 2077 - 2092
  • [46] Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)
    Gordon, K. B.
    Warren, R. B.
    Gottlieb, A. B.
    Blauvelt, A.
    Thaci, D.
    Leonardi, C.
    Poulin, Y.
    Boehnlein, M.
    Brock, F.
    Ecoffet, C.
    Reich, K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (04) : 652 - 662
  • [47] Safety and efficacy (PASI 90 and global evaluation) of subcutaneous certolizumab pegol in patients with moderate to severe chronic plaque psoriasis: Results from a double-blind, placebo-controlled trial
    Ortonne, Jean-Paul
    Reich, Kristian
    Sterry, Wolfram
    Terpstra, Ido
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB4 - AB4
  • [48] Certolizumab pegol, the first pegylated anti-TNF alpha, is effective and well tolerated in patients with moderate-to-severe chronic plaque psoriasis: preliminary data from a phase II study
    Ortonne, J.
    Sterry, W.
    Tasset, C.
    Reich, K.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 : 26 - 26
  • [49] Improvements in depression and anxiety with brodalumab therapy in AMAGINE-1, a phase 3 study for moderate to severe plaque psoriasis
    Papp, Kim
    Reich, Kristian
    Paul, Carle
    Blauvelt, Andrew
    Toth, Darryl
    Langley, Richard G.
    Cather, Jennifer
    Gottlieb, Alice
    Li, Joanne
    Kricorian, Gregory
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB254 - AB254
  • [50] Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials
    Strober, Bruce
    Warren, Richard B.
    Foley, Peter
    Gooderham, Melinda
    Thaci, Diamant
    Cullen, Eva
    Cioffi, Christopher
    Peterson, Luke
    Madden, Cynthia
    Armstrong, April
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB76 - AB76
12345